Thurston Springer Miller Herd & Titak Inc. Has $409,000 Stock Position in CVS Health Co. (NYSE:CVS)

Thurston Springer Miller Herd & Titak Inc. boosted its position in CVS Health Co. (NYSE:CVS) by 16.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,101 shares of the pharmacy operator’s stock after buying an additional 1,296 shares during the period. Thurston Springer Miller Herd & Titak Inc.’s holdings in CVS Health were worth $409,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Sound Income Strategies LLC raised its position in CVS Health by 7.2% in the 3rd quarter. Sound Income Strategies LLC now owns 2,397 shares of the pharmacy operator’s stock worth $151,000 after purchasing an additional 162 shares during the period. Hexagon Capital Partners LLC grew its stake in shares of CVS Health by 3.5% during the third quarter. Hexagon Capital Partners LLC now owns 5,268 shares of the pharmacy operator’s stock valued at $331,000 after buying an additional 178 shares during the last quarter. Bruce G. Allen Investments LLC increased its holdings in shares of CVS Health by 13.1% in the third quarter. Bruce G. Allen Investments LLC now owns 1,681 shares of the pharmacy operator’s stock worth $106,000 after buying an additional 195 shares during the period. Integrated Advisors Network LLC lifted its stake in shares of CVS Health by 0.7% in the 3rd quarter. Integrated Advisors Network LLC now owns 27,625 shares of the pharmacy operator’s stock valued at $1,737,000 after acquiring an additional 200 shares during the last quarter. Finally, Widmann Financial Services Inc. boosted its holdings in CVS Health by 1.8% during the 3rd quarter. Widmann Financial Services Inc. now owns 11,506 shares of the pharmacy operator’s stock valued at $724,000 after acquiring an additional 200 shares during the period. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Stock Up 1.1 %

NYSE:CVS opened at $52.15 on Thursday. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.80 and a quick ratio of 0.59. The firm’s 50-day moving average price is $51.68 and its 200-day moving average price is $56.44. The company has a market capitalization of $65.63 billion, a PE ratio of 13.24, a P/E/G ratio of 0.85 and a beta of 0.59. CVS Health Co. has a 1-year low of $43.56 and a 1-year high of $80.75.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.01. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. The business had revenue of $95.43 billion during the quarter, compared to the consensus estimate of $92.72 billion. During the same quarter last year, the firm earned $2.21 earnings per share. The business’s revenue for the quarter was up 6.3% on a year-over-year basis. On average, equities analysts predict that CVS Health Co. will post 5.32 EPS for the current fiscal year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Thursday, January 23rd will be issued a $0.665 dividend. This represents a $2.66 annualized dividend and a yield of 5.10%. The ex-dividend date is Thursday, January 23rd. CVS Health’s dividend payout ratio (DPR) is 67.51%.

Analyst Ratings Changes

CVS has been the subject of several recent research reports. Evercore ISI boosted their price objective on CVS Health from $62.00 to $75.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th. Truist Financial dropped their price target on shares of CVS Health from $67.00 to $60.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Wells Fargo & Company upgraded shares of CVS Health from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $60.00 to $66.00 in a research report on Monday, November 18th. Mizuho dropped their target price on shares of CVS Health from $73.00 to $66.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Finally, StockNews.com lowered CVS Health from a “hold” rating to a “sell” rating in a research report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $68.71.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.